awareness about
preventive health, the
necessity of regular
monitoring of various
health parameters and
cost and convenience
benefits, it is a no-brainer
that a major section of this
expenditure will get
onboarded to our segment
model. Market expansion
will also be triggered by
comprehensive testing.
Hence, when the share of
pathology testing reaches
$10 billion, we see home-
based testing at 15-20% of
that market.
How do you view the
latest R&D trends in
the medical
diagnostics?
With the way market is
evolving and concepts of
preventive healthcare and
monitoring gaining
importance, the sector will
continue to grow much
faster in next 5-10 years.
The gap between
innovation globally and
it’s availability in India is
fast closing and the credit
goes to growing demands
and need for R&D. There
is already a lot happening
in Cancer diagnostics in
India. Alongside
technology is going to play
a major role with machines
doing their own work, a lot
will change when artificial
intelligence using clinical
and IT algorithm is going
to be used while making
final diagnosis. The
partnerships between
technology enabled
companies, diagnostic
companies and pharma
companies is creating an
ecosystems that enables
meaningful R&D.
www.BioVoiceNews.com
33